Brookline Capital Markets initiated coverage of Constellation Pharmaceuticals (NASDAQ:CNST) with a “buy” rating and $33 price target. The stock closed at $21 on Sept 2. Constellation is using epigenetics to address...
Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...
Analysts for Canaccord Genuity, BTIG and William Blair launched coverage of Acutus Medical (NASDAQ:AFIB) with “hold”, “buy” and “outperform” ratings, respectively. Acutus is a pure-play electrophysiology company...
Brookline Capital Markets launched coverage of Forte Biosciences (NASDAQ:FBRX) with a “buy” rating and $90 price target. The stock closed at $26.69 on Aug. 27. Forte Biosciences is developing FB-401, a topical live...
H.C Wainwright launched coverage of Personalis (NASDAQ:PSNL) with a “buy” rating and $30 price target. The stock closed at $21.88 on Aug. 26. Personalis is a developer of next generation sequencing technologies and...
H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...
Brookline Capital Markets initiated coverage of 9 Meters Biopharma (NASDAQ:NMTR) with a “buy” rating and $5 price target. At midday on Aug. 20, the stock was quoted at 68 cents. 9 Meters is focused on two...
SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...
Stifel initiated coverage of Nurix Therapeutics (NASDAQ:NRIX) with a “buy” rating and $34 price target. The stock closed at $27 on Aug. 17. Nurix is a soon-to-be-clinical-stage company focused on the discovery...
Maxim Group raised its price target for TFF Pharmaceuticals (NASDAQ:TFFP) to $18 from $12, citing a new partnership with Union Therapeutics that further validates TFF’s platform potential. The stock closed at $11.55 on...